Lung cancer in never smokers is estimated to be the seventh leading cause of cancer mortality worldwide ([@bib63]), with an incidence of 10--15 cases per 100 000 person-years in the United States and Europe ([@bib70]; [@bib66]). Recognised causes of lung cancer in never smokers include second-hand smoke ([@bib28]; [@bib7]), indoor radon ([@bib47]; [@bib57]), indoor coal burning ([@bib29]), occupational carcinogens ([@bib75]) and outdoor air pollution ([@bib41]). In addition, association of lung cancer risk with genetic variants on chromosome 5p15.33 ([@bib27]; [@bib68]), 6q ([@bib3]) and 13q31.3 ([@bib38]) has been identified in never smokers. However, these known causes explain only a small proportion of never-smoking lung cancer cases ([@bib62]). There is a need to investigate other risk factors associated with lung cancer in never smokers and one potential area of further research is in carcinogenesis associated with infectious agents. This is especially relevant as there is evidence to support that chronic inflammation from factors such as infection may be involved in lung carcinogenesis ([@bib16]; [@bib61]). An infectious aetiology can be relevant to lung cancer in both ever- and never smokers, but it might be easier to identify in the latter group because of the lack of potential confounding by tobacco smoking.

Polyomaviruses are non-enveloped DNA viruses that may be potentially carcinogenic in the human lung. The first two identified human polyomaviruses -- JCV and BKV -- were first isolated in 1971 ([@bib20]; [@bib51]). From 2007 onwards, eight more human polyomaviruses have been identified ([@bib2]; [@bib21]; [@bib17]; [@bib58]; [@bib69]; [@bib9]). Serological studies till now suggest that polyomaviruses subclinically infect the general population with rates ranging from 35 to 90% Among the polyomaviruses known to date, JC virus (JCV) and Merkel cell virus (MCV) have attracted the strongest attention for a possible role in human cancer because of their presence in various tumours, their oncogenic potential in several animal models and the interaction with the Rb family of tumour suppressor genes ([@bib8]). It has been suggested that the presence of JCV correlates with lung cancer and various other human neoplasms, including colorectal, gastric, prostate, oesophageal cancers, brain tumours and B-cell lymphoma ([@bib72]; [@bib19]; [@bib54]; [@bib13], [@bib14]; [@bib26]; [@bib65]; [@bib46]). In animal studies also, there are reported pulmonary tumours derived from JCV T-antigen (TAg) in a transgenic mouse model ([@bib49]). Further investigation of polyomavirus infection in lung cancer is needed to explore a potential association.

The gold standard to investigate the role of transforming viral agents in human carcinogenesis is by detection of persistent, biologically active virus infection in the target organ. However, this is difficult to explore in lung cancer especially as tumour samples are available only from a selected group of cases undergoing surgery, and are difficult to obtain from unbiased series of non-cancer controls. In these circumstances, use of validated serological markers represents a promising alternative, especially in studies aimed at establishing the presence of an association rather than obtaining a precise estimate of its magnitude. Polyomaviruses studied so far lead to strong and over time stable antibody responses to structural viral proteins, that is, the major capsid protein VP1 ([@bib33]; [@bib5]) and are highly sensitive cumulative markers of past infection. Recently, multiplex serology assays have been developed that allows simultaneous measurement of antibody responses to multiple proteins ([@bib71]). In this analysis, we explored the role of polyomaviruses in lung cancer development in never smokers using a multiplex assay to detect serum antibodies to capsid proteins of these polyomaviruses. We have used a nested case--control design to pool data from four prospective cohort studies and also one retrospective study.

Patients and methods
====================

Study design and population
---------------------------

Our current study is a nested case--control study of cases identified from four established prospective cohorts. Never-smoking cases of lung cancer were selected among members of two prospective cohort studies of Europeans -- NYU Women\'s Health Study (WHS) ([@bib67]) and Janus Serum Bank ([@bib67]) and two prospective studies of Asians -- Shanghai Women\'s Health Study (SWHS) ([@bib77]) and Singapore Chinese Health Study (SCHS) ([@bib34]). The four cohorts have been established in the 1970s--1990s, and several rounds of follow-up have been successfully conducted, enabling the identification of incident cancer cases. Controls were matched to cases on the basis of the following established criteria: gender, never-smoking status, age at entry, calendar period of entry and other relevant criteria that are specific to each cohort (e.g. recruitment area). Consent has been obtained from all participants for future use of serum samples collected at the time of enrolment into the cohort in each of the four participating studies. We also included a retrospective case--control study in Asian Women from Xuanwei, China ([@bib36]; [@bib60]) in the secondary analysis. In this study, serum samples from cases were obtained after diagnosis. Study approval was also obtained from the Institutional Review Board at Icahn School of Medicine at Mount Sinai and from ethical review boards for each participating cohort.

Laboratory analysis
-------------------

A 100 *μ*l prediagnostic serum sample was obtained from each case and control from all four participating cohort studies and shipped to the Division of Molecular Diagnostics of Oncogenic Infections at the German Cancer Research Center (Deutsches Krebsforschungszentrum, *DKFZ*) in Heidelberg for the analysis of serological markers of infection with polyomaviruses. Serological analyses were performed by fluorescent bead-based multiplex serology as previously described ([@bib71]; [@bib33]; [@bib45]; [@bib5]), allowing simultaneous quantification of antibodies up to 100 antigens in a high-throughput assay. Briefly, full-length viral proteins were expressed in bacteria in fusion with an N-terminal glutathione *S*-transferase (GST) domain. Glutathione crosslinked to casein was covalently bound to fluorescence labelled polystyrene beads (SeroMap; Luminex Corp., Austin, TX, USA), and GST-fusion proteins were affinity-purified directly on the beads. Plasma dilutions were incubated with the same volume of mixed bead sets, at a final dilution of 1 : 000. Bound antibodies were detected with biotinylated goat--anti human IgG (H+L) secondary antibody and streptavidin-R-phycoerythrin. Beads were examined in a Luminex 200 analyzer (xMAP, Luminex Corp.) that identifies the different bead types by their internal colour and quantifies the antibody bound to the viral antigen on the different bead types via the median R-phycoerythrin fluorescence intensity (MFI) of at least 100 beads of each bead type ([@bib71]; [@bib33]). The serological analyses included viral capsid protein-1 (VP1) and T-antigens (TAg) of nine human polyomaviruses: JC virus (JCVP1, JCTAg), BK virus (BKVP1, BKTAg), KI virus (KI VP1), WU virus (WU VP1), trichodysplasia spinulosa-associated polyoma virus (TSV VP1, TSV TAg), Merkel cell polyoma virus (MCV344 VP1, MCV small T Ag, MCV large T Ag), human polyoma virus 6 (HPyV6 VP1, HPyV6 Tag), human polyoma virus 7 (HPyV7 VP1, HPyV7 Tag) and human polyoma virus 10 (HPyV10 VP1, HPyV10 TAg). With respect to serological markers of polyomavirus infection, the Pearson\'s correlation coefficients for the net MFI values for 188 sera analysed on two consecutive days for antibodies to BKV and JCV VP1 range from 0.83 to 1.00 (median, 0.96) ([@bib5]).

Statistical analysis
--------------------

To calculate the association between markers of JCV and other polyomavirus infection and lung cancer risk, odds ratios and 95% confidence intervals were calculated using logistic regression in which lung cancer status was the dependent variable (outcome) and positivity to each serological markers was the main independent variables (determinant). Seropositivity for each polyomavirus was defined as virus-specific VP1 antibody ⩾250 MFI and ⩾400 MFI for TAg (except for seropositivity for MCV small TAg where MFI⩾200 considered to be seropositive). Cut points were determined, and were chosen for each PyV by visual inspection of frequency distribution curves (percentile plots) for the inflection points of all sera tested as done in prior studies ([@bib31]; [@bib44]; [@bib52]; [@bib6]). Analyses were also repeated after stratifying by gender, race/ethnicity, histology and quantiles of the serological marker MFI. All analyses were performed using STATA 11 (College Station, TX, USA).

Results
=======

The study included 511 cases and 508 controls from four cohort studies; baseline characteristics for each study are listed in [Table 1](#tbl1){ref-type="table"}. Shanghai Women\'s Health Study included only Asian women, Janus Serum Bank included both European men (39.4%) and women (60.8%), NYU-WHS had only women mostly of European descent (79.7%), while SCHS only had Asian participants. There were variations in mean age of sample collection (range: 45.1--65.8 years) and mean age at diagnosis (range: 64.6--70.9 years) between the four studies. Another major difference in the four studies was in the time interval between sample collection and cancer diagnosis. Majority of the participants in Janus and NYU-WHS had samples collected more than 10 years before the time of cancer diagnosis. Conversely, in SCHS and SWHS studies, most of the participants had samples collected within 10 years of cancer diagnosis. Age at sample collection, gender and race/ethnicity were similar between cases and controls (*P*-value\>0.05). Addition of Xuanwei study to the analysis increased the study size to 720 cases and 717 controls. As Xuanwei was a retrospective cohort study in Asian women, the samples were collected around the time of cancer diagnosis.

The results with seropositivity for each polyomavirus are listed in [Table 2](#tbl2){ref-type="table"}. The percentage of participants seropositive for each polyomavirus was similar between cases and controls after pooling results from all four studies. Seventy per cent of the cases and 67.9% of the controls were seropositive for JCV VP1 antibody. On combining results for seropositivity to either JCV VP1 or JCV TAg, 72.0% of the cases and 71.5% of the controls were seropositive. Similarly, we found no significant differences in cases and controls for each of the polyomaviruses for VP1 antibody seropositivity as well as combined seropositivity for VP1 and TAg (positive for at least one). These seroprevalences for polyomaviruses were also similar for cases and controls after including Xuanwei study (retrospective case-control study) in the analysis. The largest histological group was adenocarcinoma (58% of all cancers) and analysis restricted only to adenocarcinoma cases and their matched controls in presented in [Table 2](#tbl2){ref-type="table"}. There were no significant differences in seropositivity for polyomaviruses on stratified analysis although the subgroups for other histologies other than adenocarcinoma were small in size.

Seropositivity for each polyomavirus VP1 stratified by study is listed in [Table 3](#tbl3){ref-type="table"}. In the stratified analysis by study, seroprevalence for each polyomavirus showed significant heterogeneity by study but overall there were no statistical significant differences between cases and controls in any of the five studies. For instance, MCV showed seroprevalence against VP1 in cases ranging from 36.0 to 76.7%. Overall, seropositivity for each polyomavirus was higher in the Asian Cohorts compared with cohorts with Caucasian patients. For example, seropositivity for JCV VP1 in Janus study (predominantly Caucasian) was 59.5% in cases compared with 77.2% in SWHS and 75.4% in SCHS (Asian cohorts).

In addition, we did not find any differences in seropositivity between cases and controls in our stratified analysis based on time interval from sample collection to cancer diagnosis ([Table 4](#tbl4){ref-type="table"}) or gender. We also divided the participants based on their MFI into quartiles for each polyomavirus and then compared the mean MFI between the quartiles for cases and controls to explore for any potential association between antibody levels and seropositivity. However, cases and controls did not differ significantly in any of these analyses.

Discussion
==========

Our study is the largest epidemiological study in never smokers to investigate if infection with polyomaviruses as measured by seroprevalence and quantity of antibodies against viral structural proteins are associated with lung cancer risk. After pooling serological results from four cohort studies using a nested case--control design, we did not find any significant differences in serological measurements of antibodies against each of the polyomaviruses between the cases and controls. Similar results were obtained from an additional retrospective case--control study. Our results do not support the hypothesis that seropositivity for polyomaviruses is associated with increased lung cancer risk in never smokers.

Serological studies have indicated asymptomatic JCV infection in up to 80--90% of the adult population ([@bib72]; [@bib12]), which is similar to that reported in our analysis and, which may be activated in immunodeficient patients, resulting in progressive multifocal leukoencephalopathy ([@bib18]; [@bib73], [@bib74]). JC virus can transform cells, as shown by effects such as growth in agar, rapid division, prolongation of life span, unstable multicentric chromosomes, centric and acentric rings, and the ability to form dense foci in culture ([@bib18]). Intravenous or intracranial inoculation of JCV into experimental animals has been found to cause astrocytomas, glioblastomas, neuroblastomas and medulloblastomas ([@bib54]). In addition, transgenic mice expressing the JCV T-antigen developed pituitary adenomas or malignant peripheral nerve sheath tumours ([@bib23]; [@bib54]). The molecular mechanisms underlying oncogenesis by JCV could centre on its encoded regulatory products, T-antigens and agnoprotein. The JCV T-antigen can inactivate p53 and members of the pRb family, and deregulate the Wnt signalling pathway through stabilisation of *β*-catenin to promote uncontrolled proliferation and immortal survival ([@bib56]; [@bib32]; [@bib48]; [@bib74]). A number of studies investigating JCV in lung cancer tissue samples have been performed. In a Japanese analysis of JCV TAg in 103 lung carcinomas and 18 normal lung tissues, 68% of lung carcinomas were positive, compared with only 11% of normal lung tissue (*P*\<0.05), indicating that JCV may be involved in lung carcinogenesis ([@bib76]). In another study by the same group, 25 of 62 lung cancers had TAg compared with only 4 of 23 normal lung tissues (*P*=0.048) ([@bib1]). In contrast, an Italian study reported that only one tumour sample out of 78 was positive ([@bib22]). KI and WU polyomaviruses have also been identified in respiratory tract specimens, especially in children with respiratory tract infections ([@bib55]; [@bib50]). This raises the question whether KI or WU subclinical infection in the respiratory tract may lead to chronic inflammatory changes and ultimately lung carcinogenesis. Merkel cell virus is associated with Merkel cell carcinomas in immunocompromised hosts ([@bib17]). There have been studies conducted to investigate the prevalence of MCV in lung tumours and these have shown variable results with some studies showing MCPyV DNA present in more than 15% of the tumours ([@bib30]). One of these studies also demonstrated the expression of large T RNA transcripts and antigen in lung cancer, thus indicating possible viral integration ([@bib25]). A Greek study also reported MCV DNA in 9.1% of lung tumours. Moreover, increased BRAF expression and decreased Bcl-2 expression were noted in MCV DNA-positive samples ([@bib37]). These results suggest that viral DNA integration may potentially activate cancer pathways and is an area for future investigation.

Recent developments have resulted in increased specificity and sensitivity of serological markers of past infection with known and suspected oncogenic viruses. Multiplex serology allows quantitative analysis of antibodies to multiple recombinant structural and regulatory proteins in parallel in a high-throughput fashion ([@bib15]; [@bib71]). This increases the sensitivity and in comparison with conventional screening ELISA increases the specificity of antibody detection as it has been shown for HPV ([@bib15]; [@bib71]), polyomaviruses ([@bib33]) and *Helicobacter pylori* ([@bib45]). The protein antigens used in the assay for our analysis have been shown to allow very sensitive and virus-type-specific antibody detection ([@bib71]; [@bib33]; [@bib52]; [@bib39]; [@bib64]). Moreover, there is ample evidence supporting the use of serological markers in detection of polyomaviruses. Systemic infections, as observed with all polyomaviruses studied so far, lead to strong and over time stable antibody responses to structural viral proteins, that is, the major capsid protein VP1 ([@bib33]; [@bib5]) and are thus highly sensitive cumulative markers of past infection, while antibodies to polyomaviral T-Antigens are rare and usually of low titer. However, strong antibody responses to the large TAg of MCV have been found to be very significantly associated with Merkel cell carcinoma ([@bib52]). Development of strong antibody responses to oncogenic proteins E6 and E7 has also been observed in patients with HPV-associated cervical ([@bib43]) or oropharyngeal ([@bib78]; [@bib39]) cancers, thus suggesting that antibodies to early, transformation-associated proteins could be diagnostic markers for malignancies driven by these viral oncogenes.

One strength of our study is the large sample size after pooling data and samples from five large lung cancer studies in comparison with previous studies exploring association between lung cancer and infectious agents ([@bib40]; [@bib10]; [@bib35]; [@bib4]). Moreover, in four of the five studies, we had access to samples collected before tumour development, thus avoiding potential bias from reverse causality and inadequate selection of controls. Our study also had a representation from different geographical areas. Moreover, in addition to JCV and BKV, we report the seroprevalence results for seven other human polyomaviruses that have been identified recently (after 2007) and, therefore, data for these polyomaviruses in literature are limited. One limitation of our study is that the MFI cutoff value used to determine seropositivity in this study is somewhat arbitrary, although carefully examined ([@bib24]). We did perform sensitivity analyses and found the seroprevalence data to be very robust to alterations in the cutoff. Also, we observed variation on seroprevalence of polyomaviruses based on ethnicity and geographical area which may make the interpretation of results difficult. In addition, we did not adjust for other potential confounders such as second-hand smoking and radon exposure as data for these confounders were not available across all five studies. We also did not adjust for multiple comparisons, but this may not be clinically relevant as we did not find significant association between polyomaviruses seroprevelence and lung cancer risk. We have not included measurement of polyomavirus Simian virus 40 (SV 40) seroprevalence in our study. Simian virus 40 seroprevalence has been reported to be anywhere between 9 and 12.7% in the general population and higher at 26% in patients with malignant mesothelioma in some studies ([@bib53]; [@bib42]; [@bib11]). However, other studies with conflicting results have shown that this low level seroprevalnce to SV40 is actually an artefact due to cross-reactivity with other related human polyomaviruses such as BKV and JCV ([@bib53]; [@bib33]; [@bib59]).

In conclusion, we did not find an increased lung cancer risk is association with seropositivity for polyomaviruses including JCV. Therefore, future research should focus on exploring viral replication in tumour in combination with serological markers of infection especially as polyomavirus exposure can vary considerably across different populations and geographical areas as demonstrated by our study.
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###### Baseline characteristics of participating studies

                                                                     **Cases**[a](#t1-fn2){ref-type="fn"} (***n*****=511)**   **Controls**[a](#t1-fn2){ref-type="fn"} (***n*****=508)**    **Janus**    **NYU-WHS**    **SCHS**      **SWHS**     **Xuanwei study**[b](#t1-fn3){ref-type="fn"}
  ----------------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------- ------------- ------------- ------------- ------------- ----------------------------------------------
  *n*, Cases/controls                                                                          --                                                        --                                 126/124        64/64        114/114       207/206                       209/209
  Age at sample collection                                                                                                                                                                                                                                              
   Mean±s.d.                                                                               56.0±11.0                                                  56.1±11.1                            45.1±8.7      55.0±8.1      65.8±7.8      57.7±8.50                      50.7±9.6
  Gender                                                                                                                                                                                                                                                                
   Female                                                                                 433 (84.7%)                                                430 (84.7%)                          152 (60.8%)   128 (100%)    170 (74.6%)   413 (100%)                     418 (100%)
  Race/ethnicity                                                                                                                                                                                                                                                        
   White                                                                                  177 (34.6%)                                                175 (34.5%)                          250 (100%)    102 (79.7%)       --            --                             --
   Asian                                                                                  322 (63.0%)                                                321 (63.2%)                              --         2 (1.6%)     228 (100%)    413 (100%)                     418 (100%)
   Other                                                                                   12 (2.4%)                                                  12 (2.3%)                               --        24 (18.8%)        --            --                             --
  Age at diagnosis                                                                                                                                                                                                                                                      
   Mean±s.d.                                                                                66.9±9.9                                                     --                                65.3±11.0     70.9±9.4      70.5±8.1      64.6±9.2                       50.6±9.4
  Histology                                                                                                                                                                                                                                                             
   Adenocarcinoma                                                                         592 (58.1%)                                                    --                               65 (51.6%)     32 (50%)     74 (64.9%)    127 (61.4%)                   185 (88.5%)
   Squamous cell                                                                           54 (5.2%)                                                     --                                7 (5.6%)      5 (7.8%)      5 (4.4%)      10 (4.8%)                     24 (11.5%)
   Small cell                                                                             214 (21.0%)                                                    --                               13 (10.3%)    11 (17.2%)    20 (17.5%)    63 (30.4%)                         --
  Interval between sample collection and cancer diagnosis (years)                                                                                                                                                                                                       
   ⩽5                                                                                     135 (26.4%)                                                    --                                9 (7.1%)      4 (6.3%)     61 (53.5%)    61 (29.5%)            [b](#t1-fn3){ref-type="fn"}
   5--10                                                                                  172 (33.7%)                                                    --                                7 (5.6%)     10 (15.6%)    49 (42.3%)    106 (51.2%)                        --
   \>10                                                                                   204 (39.9%)                                                    --                               110 (87.3%)   50 (78.1%)     4 (3.5%)     40 (19.3%)                         --

Abbreviations: Janus=Janus Serum Bank; *n*=number; NSCLC=non-small cell lung cancer; NYU-WHS=NYU Women\'s Health Study; SCHS=Singapore Chinese Health Study; SWHS=Shanghai Women\'s health study; s.d.=standard deviation.

Studies included in primary analysis -- Janus, NYU-WHS, SCHS, SWHS.

Xuanwei study is a retrospective cohort study so samples were collected after the time of cancer diagnosis.

###### Seropositivity of polyomaviruses and association with lung cancer

                                                **Cases**   **Controls**                                   
  -------------------------------------------- ----------- -------------- ----- ------ ------------------- ------
  JCV (VP1)                                        353          69.1       349   68.7   1.02 (0.78--1.33)   0.90
  JCV (VP1±TAg)                                    368          72.0       363   71.5   1.03 (0.78--1.35)   0.84
  BKV (VP1)                                        455          89.0       456   89.8   0.93 (0.62--1.38)   0.71
  BKV (VP1±TAg)                                    455          89.0       456   89.8   0.93 (0.62--1.38)   0.71
  KI (VP1)                                         434          84.9       445   87.6   0.80 (0.56--1.14)   0.22
  WU (VP1)                                         490          95.9       492   96.9   0.76 (0.39--1.47)   0.41
  TSV (VP1)                                        391          76.5       387   76.2   1.02 (0.76--1.36)   0.90
  TSV (VP1±TAg)                                    392          76.7       388   76.4   1.02 (0.76--1.36)   0.13
  MCV (VP1)                                        303          59.3       313   61.6   0.91 (0.71--1.17)   0.45
  MCV (VP1±small TAg±large TAg)                    305          59.7       314   61.8   0.91 (0.71--1.18)   0.49
  HPyV6 (VP1)                                      393          76.9       399   78.5   0.91 (0.68--1.22)   0.53
  HPyV6 (VP1±TAg)                                  393          76.9       400   78.7   0.90 (0.67--1.21)   0.48
  HPyV7 (VP1)                                      330          64.6       332   65.4   0.97 (0.75--1.25)   0.80
  HPyV7 (VP1±TAg)                                  333          65.2       334   65.8   0.97 (0.75--1.26)   0.85
  HPyV10 (VP1)                                     492          96.3       496   97.6   0.63 (0.30--1.30)   0.21
  HPyV10 (VP1±TAg)                                 492          96.3       497   97.8   0.57 (0.27--1.22)   0.15
  **Analysis including adenocarcinoma only**                                                               
  JCV (VP1)                                        207          69.5       196   66.7   1.14 (0.80--1.61)   0.47
  JCP (VP1±TAg)                                    216          72.5       204   69.4   1.16 (0.81--1.66)   0.41
  BKV (VP1)                                        265          88.9       268   91.2   0.78 (0.45--1.34)   0.37
  BKV (VP1±TAg)                                    265          88.9       268   91.2   0.78 (0.45--1.34)   0.37
  KI (VP1)                                         251          84.3       258   87.8   0.75 (0.47--1.19)   0.22
  WU (VP1)                                         285          95.6       287   97.6   0.53 (0.21--1.36)   0.19
  TSV (VP1)                                        230          77.2       219   74.5   1.16 (0.79--1.69)   0.44
  TSV (VP1±TAg)                                    230          77.2       220   74.8   1.14 (0.78--1.66)   0.5
  MCV (VP1)                                        162          54.4       184   62.6   0.71 (0.51--0.99)   0.04
  MCV (VP1±small TAg±large TAg)                    163          54.7       184   62.6   0.72 (0.52--1.00)   0.05
  HPyV6 (VP1)                                      226          75.8       239   81.3   0.72 (0.49--1.07)   0.11
  HPyV6 (VP1±TAg)                                  226          75.8       240   81.6   0.71 (0.47--1.05)   0.09
  HPyV7 (VP1)                                      188          63.1       204   69.4   0.75 (0.54--1.06)   0.11
  HPyV7 (VP1±TAg)                                  190          63.8       205   69.7   0.76 (0.54--1.08)   0.12
  HPyV10 (VP1)                                     282          94.6       285   96.9   0.56 (0.24--1.28)   0.17
  HPyV10 (VP1±TAg)                                 282          94.6       286   97.3   0.49 (0.21--1.17)   0.11

Abbreviations: BKV=BK virus; CI=confidence interval; HPyV6=human polyoma virus 6; HPyV7=human polyoma virus 7; HPyV10=human polyoma virus 10; JCV=JC virus; MCV=Merkel cell polyoma virus; *n*=number; TSV=trichodysplasia spinulosa-associated polyoma virus.

Studies included in primary analysis -- Janus, NYU-WHS, SCHS, SWHS.

Seropositivity for each polyomavirus VP1 defined as MFI⩾250 and MFI⩾400 for each TAg (except for MCV small Ag where seropositivity⩾200 MFI).

###### Seropositivity of polyomaviruses and association with lung cancer stratified by participating study

                       **Cases**   **Controls**                                              
  ------------------- ----------- -------------- ----- ------- ----------------------------- ------
  **Janus**                                                                                  
  JCV (VP1)               75           59.5       77    62.1         0.90 (0.54--1.49)        0.68
  BKV (VP1)               105          83.3       106   85.5         0.85 (0.43--1.68)        0.64
  KI (VP1)                113          89.7       116   93.6         0.60 (0.24--1.50)        0.28
  WU (VP1)                119          94.4       118   95.2         0.86 (0.28--2.65)        0.8
  TSV (VP1)               100          79.4       99    79.8         0.97 (0.52--1.80)        0.93
  MCV (VP1)               84           66.7       79    63.7         1.14 (0.68--1.92)        0.62
  HPyV6 (VP1)             97           77.0       98    79.0         0.89 (0.49--1.62)        0.7
  HPyV7 (VP1)             69           54.8       78    62.9         0.71 (0.43--1.18)        0.19
  HPyV10 (VP1)            126         100.0       124   100.0   [a](#t3-fn3){ref-type="fn"}     
  **NYU-WHS**                                                                                
  JCV (VP1)               34           53.1       35    54.7         0.94 (0.47--1.88)        0.86
  BKV (VP1)               55           85.9       57    89.1         0.75 (0.26--2.16)        0.59
  KI (VP1)                57           89.1       57    89.1          1 (0.33--3.03)          1.00
  WU (VP1)                56           87.5       63    98.4         0.11 (0.01--0.92)        0.04
  TSV (VP1)               42           65.6       44    68.8         0.87 (0.42--1.82)        0.71
  MCV (VP1)               51           79.7       49    76.6         1.20 (0.52--2.78)        0.67
  HPyV6 (VP1)             49           76.6       47    73.4         1.18 (0.53--2.63)        0.68
  HPyV7 (VP1)             37           57.8       36    56.3         1.07 (0.53--2.15)        0.86
  HPyV10 (VP1)            64          100.0       63    98.4    [a](#t3-fn3){ref-type="fn"}     
  **SWHS**                                                                                   
  JCV (VP1)               156          75.4       151   73.3         1.11 (0.72--1.73)        0.63
  BKV (VP1)               193          93.2       188   91.3         1.32 (0.64--2.73)        0.45
  KI (VP1)                183          88.4       182   88.4         1.01 (0.55--1.84)        0.99
  WU (VP1)                206          99.5       204   99.0        2.02 (0.18--22.45)        0.57
  TSV (VP1)               164          79.2       163   79.1         1.01 (0.63--1.62)        0.98
  MCV (VP1)               127          61.4       138   67.0         0.78 (0.52--1.17)        0.23
  HPyV6 (VP1)             156          75.4       169   82.0         0.67 (0.42--1.08)        0.1
  HPyV7 (VP1)             148          71.5       146   70.9         1.03 (0.67--1.58)        0.89
  HPyV10 (VP1)            199          96.1       201   97.6         0.62 (0.20--1.92)        0.41
  **SCHS**                                                                                   
  JCV (VP1)               88           77.2       86    75.4         1.10 (0.60--2.03)        0.76
  BKV (VP1)               102          89.5       105   92.1         0.73 (0.29--1.80)        0.49
  KI (VP1)                81           71.1       90    79.0         0.65 (0.36--1.20)        0.17
  WU (VP1)                109          95.6       107   93.9         1.43 (0.44--4.63)        0.56
  TSV (VP1)               85           74.6       81    71.1         1.19 (0.67--2.14)        0.55
  MCV (VP1)               41           36.0       47    41.2         0.80 (0.47--1.37)        0.42
  HPyV6 (VP1)             91           79.8       85    74.6         1.35 (0.72--2.51)        0.34
  HPyV7 (VP1)             76           66.7       72    63.2         1.17 (0.68--2.01)        0.58
  HPyV10 (VP1)            103          90.4       108   94.7         0.52 (0.19--1.46)        0.21
  **Xuanwei study**                                                                          
  JCV (VP1)               153          73.2       170   81.3         0.63 (0.39--1.00)        0.05
  BKV (VP1)               160          76.6       161   77.0         0.97 (0.62--1.53)        0.91
  KI (VP1)                190          90.9       186   89.0         1.24 (0.65--2.35)        0.52
  WU (VP1)                208          99.5       207   99.0        2.01 (0.18--22.33)        0.57
  TSV (VP1)               181          86.6       181   86.6          1 (0.57--1.76)           1
  MCV (VP1)               113          54.1       101   48.3         1.26 (0.86--1.85)        0.24
  HPyV6 (VP1)             58           27.8       68    32.5         0.80 (0.52--1.21)        0.29
  HPyV7 (VP1)             23           11.0       19     9.1         1.24 (0.65--2.35)        0.52
  HPyV10 (VP1)            193          92.3       197   94.3         0.73 (0.34--1.59)        0.44

Abbreviations: BKV=BK virus; CI=confidence interval; HPyV6=human polyoma virus 6; HPyV7=human polyoma virus 7; HPyV10=human polyoma virus 10; JCV=JC virus; MCV=Merkel cell polyoma virus; *n*=number; TSV=trichodysplasia spinulosa-associated polyoma virus.

Seropositivity for each polyomavirus VP1 defined as MFI⩾250 and MFI⩾400 for each TAg (except for MCV small TAg where seropositive if MFI⩾200).

Odds ratio cannot be calculated as 100% seropositivity for polyomavirus in cases.

###### Seropositivity of polyomaviruses and association with lung cancer stratified by interval between sample collection and cancer diagnosis

                     **Cases** ***n*** **(%)**   **Controls** ***n*** **(%)**   **Odds ratio (95% CI)**   ***P*****-value**
  ----------------- --------------------------- ------------------------------ ------------------------- -------------------
  ⩽**5 years**                                                                                           
  JCV (VP1)                 101 (74.8)                    98 (73.1)                1.09 (0.63--1.88)            0.75
  BKV (VP1)                 125 (92.6)                    119 (88.8)               1.58 (0.68--3.64)            0.29
  KI (VP1)                  109 (80.7)                    109 (81.3)               0.96 (0.52--1.77)             0.9
  WU (VP1)                  131 (97.0)                    128 (95.5)               1.54 (0.42--5.57)            0.51
  TSV (VP1)                 100 (74.1)                    101 (75.4)               0.93 (0.54--1.62)            0.81
  MCV (VP1)                  75 (55.6)                    74 (55.2)                1.01 (0.63--1.64)            0.96
  HPyV6 (VP1)               105 (77.8)                    102 (76.1)               1.10 (0.62--1.94)            0.75
  HPyV7 (VP1)                92 (68.2)                    83 (61.9)                1.31 (0.80--2.17)            0.29
  HPyV10 (VP1)              129 (95.6)                    126 (94.0)               1.37 (0.46--4.05)            0.58
  **5--10 years**                                                                                        
  JCV (VP1)                 131 (76.2)                    125 (72.7)               1.20 (0.74--1.95)            0.46
  BKV (VP1)                 155 (90.1)                    159 (92.4)               0.75 (0.35--1.58)            0.45
  KI (VP1)                  142 (82.6)                    155 (90.1)               0.52 (0.27--0.98)            0.04
  WU (VP1)                  169 (98.3)                    167 (97.1)               1.69 (0.40--7.17)            0.48
  TSV (VP1)                 138 (80.2)                    127 (73.8)               1.44 (0.87--2.39)            0.16
  MCV (VP1)                  89 (51.7)                    102 (59.3)               0.74 (0.48--1.13)            0.16
  HPyV6 (VP1)               133 (77.3)                    145 (84.3)               0.64 (0.37--1.09)             0.1
  HPyV7 (VP1)               115 (66.9)                    119 (69.2)               0.90 (0.57--1.41)            0.64
  HPyV10 (VP1)              162 (94.2)                    169 (98.3)               0.29 (0.08--1.06)            0.06
  **\>10 years**                                                                                         
  JCV (VP1)                 121 (59.3)                    126 (62.4)               0.88 (0.59--1.31)            0.53
  BKV (VP1)                 175 (85.8)                    178 (88.1)               0.81 (0.46--1.45)            0.49
  KI (VP1)                  183 (89.7)                    181 (89.6)               1.01 (0.53--1.92)            0.97
  WU (VP1)                  190 (93.1)                    197 (97.5)               0.34 (0.12--0.97)            0.05
  TSV (VP1)                 153 (75.0)                    159 (78.7)               0.81 (0.51--1.29)            0.38
  MCV (VP1)                 139 (68.1)                    137 (67.8)               1.01 (0.67--1.54)            0.95
  HPyV6 (VP1)               155 (76.0)                    152 (75.3)               1.04 (0.66--1.64)            0.86
  HPyV7 (VP1)               123 (60.3)                    130 (64.4                0.84 (0.56--1.26)             0.4
  HPyV10 (VP1)               201 (98.5                    201 (99.5                0.33 (0.03--3.23)            0.34

Abbreviations: BKV=BK virus; CI=confidence interval; HPyV6=human polyoma virus 6; HPyV7=human polyoma virus 7; HPyV10=human polyoma virus 10; JCV=JC virus; MCV=Merkel cell polyoma virus; *n*=number; TSV=trichodysplasia spinulosa-associated polyoma virus.

Seropositivity for each polyomavirus VP1 defined as MFI⩾250 and MFI⩾400 for each TAg (except for MCV small TAg where seropositive if MFI⩾200).
